Xconomy |
Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal
Xconomy BD's $12.4 billion in revenue last year was split between its Medical Segment, which makes diabetes care products and devices used by clinicians to manage and administer medication, and its Life Sciences Segment that sells products for collecting and ... |
Social Plugin